
Opinion|Videos|June 20, 2024
DESTINY-Breast04: Trastuzumab Deruxtecan in HR+/HER2-Low Metastatic Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Please review key efficacy and safety data from the DESTINY-Breast04 trial, evaluating trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low metastatic breast cancer.
- What are the clinical implications of these data in your practice?
- What notable adverse events (AEs) have you observed in your practice?
- What mitigation strategies have been implanted in your practice to combat AEs of special interest?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































